Pregled bibliografske jedinice broj: 665983
Osteogenic potential and stemness of mesenchymal stem cells after dexamethasone treatment
Osteogenic potential and stemness of mesenchymal stem cells after dexamethasone treatment // Book of Abstracts
Opatija, Hrvatska, 2012. (poster, međunarodna recenzija, sažetak, ostalo)
CROSBI ID: 665983 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Osteogenic potential and stemness of mesenchymal stem cells after dexamethasone treatment
Autori
Matić I, Ivković A, Brkić Š, Josipović P, Karlak I, Pećina M, Marijanović I.
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo
Izvornik
Book of Abstracts
/ - , 2012
Skup
2nd International Conference on Regenerative Orthopaedics and Tissue Engineering
Mjesto i datum
Opatija, Hrvatska, 20.09.2012. - 22.09.2012
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
MSC; stemness; dexamethasone
Sažetak
The purpose of the research was to improve osteogenic differentiation of human bone marrow derived-mesenchymal stem cells (hMSCs) and to evaluate the level of remaining undifferentiated stem cells in culture. Standard cell culture protocol includes continuous exposure to the dexamethasone which is not easy to reproduce in human body. Therefore, our experiment was designed to investigate the possibility of using short-term dexamethasone exposure in order to induce osteogenic differentiation. Human bone marrow-derived MSCs were expanded with FGF-2 supplemented media. Afterwards cells were cultured in osteogenic media (DMEM low glucose, 10% FBS, 10mM β-glycerophosphate, 5μg/ml ascorbic acid, 1mM piruvat) and treated with different concentrations of dexamethasone, both short-term and continuous. The differentiation status of the cells was estimated using several osteogenic markers - alkaline phosphatase (AP) activity, the bone sialoprotein (BSP) and dentin matrix protein 1 (DMP-1) mRNAs. The stemness of the cells was estimated by the presence of pluripotency markers - SRY (sex determining region Y)-box 2 (SOX2) and octamer-binding transcription factor 4 (OCT4). The measurements were conducted on the days 7 and 14 after osteogenic conditions had been introduced. Our results show that continuous treatment induces the highest level of osteogenesis, but 2 hour exposure also induced differentiation in comparison with control. Overall, 10-5 M concentration of dexamethasone was the most powerful in the short-term induction of osteogenesis. SOX2 has not been detected in hMSCs. OCT4 was expressed in undifferentiated pluripotent hMSCs and its expression subsequently went down, indicating that the differentiation process is proceeding
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
108-0000000-3652 - Genska terapija mineraliziranih tkiva (Pećina, Marko, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb,
Prirodoslovno-matematički fakultet, Zagreb,
Klinička bolnica "Sveti Duh",
Klinika za traumatologiju